Key result
Exosome-based therapeutics show promise for cardiovascular disease treatment, though clinical translation requires improved targeting, scalable manufacturing, and regulatory standardization.
Why the study?
Exosomes are emerging as a potential therapy for cardiovascular disease, warranting a comprehensive overview of recent advancements in their separation, characterization, and therapeutic applications.
Exosome-based therapeutics represent a promising regenerative approach for cardiovascular disease, but significant translational challenges remain regarding manufacturing and standardization.
Exosome therapies for CVD remain experimental; leaves open clinical translation pending rigorous trials.
Given that exosomes may carry bioactive chemicals, facilitate cell communication, and stimulate tissue regeneration, they are becoming more and more popular as a potential therapy option for cardiovascular disease (CVD). With an emphasis on their separation, characterization, and therapeutic uses in illnesses including myocardial infarction, heart failure, and atherosclerosis, this review attempts to provide a thorough overview of recent advancements in exosome-based therapeutics for CVD. Using databases such as PubMed, Scopus, and Google Scholar, a comprehensive search of peer-reviewed literature from 2015 to 2024 was carried out using keywords such as “exosome-based therapeutics,” “cardiovascular disease,” and “myocardial infarction.” Exosome separation, cargo identification, and therapeutic promise in preclinical and clinical settings were the main criteria used to choose the studies. The review summarizes the main conclusions and talks about the difficulties in clinical translation as well as the mechanisms of exosome-mediated effects such as microRNA and protein transfer. To maximize the therapeutic effectiveness of exosome-based therapeutics in CVD, it also identifies future approaches for these treatments, addressing the need for better targeting, scalable manufacturing, and regulatory standardization.
No takes yet. Share an insight, caveat, or question.
Omar Elsaka (2025) conducted a review in Cardiovascular disease. Exosome-based therapeutics was evaluated. Exosome-based therapeutics show promise for cardiovascular disease treatment, though clinical translation requires improved targeting, scalable manufacturing, and regulatory standardization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: